Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Monitoring with Vaccine and Antigen Challenges in Healthy Volunteers
NCT03953196Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of JYNNEOS, Zoster vaccine recombinant, escherichia coli endotoxin and candida albicans antigen (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from Baseline of Immune Cell Populations at 10 days, Change from Baseline in Cell Surface Antigen Phenotype at 10 days and 3 more. Started Apr 2019; status: completed.
02
Drugs
JYNNEOSZoster vaccine recombinantescherichia coli endotoxincandida albicans antigen
Beyond the preview
Go deeper on NCT03953196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953196.